QCDx News

06.22.2020
QCDx presents poster at the AACR 2020 Meeting, on supporting work ahead of a clinical study for a novel breast cancer diagnostic.

At the Annual Meeting of the American Association for Cancer Research (AACR) on June 22, 2020, QCDx presented results from a study demonstrating the RareScope’s ability to detect rare cancer cells at frequencies expected in both early stage and metastatic disease in the blood of breast cancer patients. The results support the utilization of RareScope in the UConn IRB-approved clinical study for a novel breast cancer diagnostic. 

The abstract will be included in an online-only Proceedings supplement to the AACR journal Cancer Research following the AACR Virtual Annual Meeting II.

Read Full Poster

01.21.2020
QCDx Announces Sale of the RareScope to the Carole and Ray Neag Comprehensive Cancer Center at UConn Health for Use in Clinical Research

QCDx is excited to grow its collaboration with the UConn Cancer Center and come to an agreement with Dr. Pramod K. Srivastava PhD MD, Director of the Carole and Ray Neag Comprehensive Cancer Center at UConn Health, for the procurement of a RareScope instrument combined with RarePicker cell isolation.

"The RareScope can detect and isolate intact and live Circulating Tumor Cells from a blood sample of

a cancer patient after analyzing every single nucleated cell,” said Dr. Srivastava. “We intend to use the ability of the RareScope to obtain a deep look into the genomes of cancer cells in patients undergoing standard-of-care and experimental treatments".

Read Full PressRelease

11.21.2019
 
Dr. George Church becomes QCDx Lead Scientific Advisor

We are honored to have Dr. George Church, an illustrious colleague, join QCDx LLC as the Lead Scientific Advisor.

His multidisciplinary expertise in the interface of biology and technology including in robotic microscopy, in vitro pathologic development and lineage phylogenetics will provide an enormous boost for bringing our technology to the cancer patient’s bedside.

Dr. Church, a Professor of Genetics at Harvard Medical School, and Professor of Health Sciences and Technology at the Massachusetts Institute of Technology and Harvard Medical School, is a pioneer of genome engineering, DNA sequencing and synthetic biology. 

11.19.2019
UConn Institutional Review Board approves breast cancer diagnostic study

QCDx and the UConn Carole & Ray Neag Cancer Center with Dr. Susan Tannenbaum Principal Investigator, received approval by the UConn IRB of the prospective breast cancer diagnostic clinical study "Determination of the Potential Clinical Utility of the QCD:x-br™ Liquid Biopsy Technology to Optimize Treatment Options for Breast Cancer Patients". The study is scheduled to enroll 30 early stage and 30 metastatic patients.

For each patient, repeated blood samples will be collected during and after treatment. The goal is to assess correlations between CTCs of different phenotypes and the disease status. Detection will be done with the RareScope after fluorescence immunostaining for epithelial and mesenchymal CTC markers as well as markers related to hormone or targeted treatment. Available biopsied tissue will be analyzed by next generation sequencing offered commercially by Tempus Laboratories (Chicago, IL). The study is co-sponsored by the CT Breast Health Initiative.

11.13.2019
Dr. Enrique Ballesteros MD joins QCDx as our Clinical Pathology Advisor

Dr., Ballesteros is joining QCDx to provide leading Medical Oncology expertise and guide development of clinical diagnostic assays utilizing the RareScope technology platform. 

Continuing the development of the RareScope platform, QCDx will assess clinical validity for the detection of CTCs in the blood of cancer patients. Dr. Tannenbaum will be the Principal Investigator of a study that will be conducted in collaboration with the UConn Carol & Ray Neag Comprehensive Cancer Center to explore clinical validity and potentially clinical utility of the RareScope in optimizing treatment options for breast cancer patients.

Dr. Tannenbaum will advise QCDx on other projects aiming to show the RareScope value for diagnostic applications in other cancers and for cancer research programs.

07.15.2019
Dr. Susan Tannenbaum MD becomes QCDx Medical Oncology Advisor

Dr., Tannenabum is joining QCDx to provide leading Medical Oncology expertise and guide development of clinical diagnostic assays utilizing the RareScope technology platform. 

Continuing the development of the RareScope platform, QCDx will assess clinical validity for the detection of CTCs in the blood of cancer patients. Dr. Tannenbaum will be the Principal Investigator of a study that will be conducted in collaboration with the UConn Carol & Ray Neag Comprehensive Cancer Center to explore clinical validity and potentially clinical utility of the RareScope in optimizing treatment options for breast cancer patients.

Dr. Tannenbaum will advise QCDx on other projects aiming to show the RareScope value for diagnostic applications in other cancers and for cancer research programs.

05.05.2019
Sir Walter Bodmer FRS, HonFRSE, FMedSci will be QCDx Mentor and Advisor for the development of RareScope applications

Sir Walter is a long-term Scientific Mentor for QCDx’s founders.

He has vast experience and decades of research in the fundamental genetics and biology of colorectal cancer (CRC) and their applications. As an experimental researcher in his substantial studies  of cancer related cellular pathways he was involved with the development of numerous antibodies against cancer related proteins and he will provide valuable guidance for the detection of rare cells in cancer related projects.

Sir Walter will also provide insights in other areas where the QCDx rare cell detection technology can be of value, such as in the prenatal detection of congenital anomalies or other congenital conditions.  

©2018-2020 by QCDx LLC